GHK-Cu: what the FDA says

Not covered by the October 28, 2026 HHS policy. What the policy covers

What the FDA's lists say

For injection, the FDA lists GHK-Cu among substances that were in Category 2, its list of substances that may present significant safety risks, and whose nominations were then withdrawn. For other routes, GHK-Cu is on the FDA's Category 1 list, and the FDA says it intends to ask its compounding advisory committee about GHK-Cu before the end of February 2027.

The FDA's own note on GHK-Cu, on that list:

"Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations."

Source: FDA list of bulk drug substances that may present significant safety risks (current as of April 22, 2026); FDA's 503A category lists (current as of May 14, 2026).

GHK-Cu is not on our chart. The cheapest peptide we price:

Cheapest sermorelin on our chart

Tied at $99 a month: CoreAge Rx, Embody, Lttl, Strut Health and Villas Health.

  1. CoreAge Rx logoCoreAge Rxfrom $99 a month, no membership fee. No long-term contractSermorelin injectionChecked November 21, 2026 on CoreAge Rx's own pageCheck price at CoreAge Rx →
  2. Embody logoEmbody$99 a month, after a $49 first monthSermorelin injectionChecked November 21, 2026 on Embody's own pageCheck price at Embody →
  3. Lttl logoLttlfrom $99 a month, visits included. The plan is set at checkoutSermorelin injectionChecked November 21, 2026 on Lttl's own pageCheck price at Lttl →
  4. Strut Health logoStrut Health$99 a month, on auto-refillSermorelin lozengeChecked November 21, 2026 on Strut Health's own pageCheck price at Strut Health →
  5. Villas Health logoVillas Health$99 a month, monthly subscription; $119 as a one-time purchaseSermorelin injectionChecked November 21, 2026 on Villas Health's own pageSee prices

Prices checked by The Pep Chart on , from each program's own page. How we check prices | How we make money

FDA status of every peptide we track